Aggressive breast cancer is a type of breast cancer that spreads quickly and can result in high mortality rate if not treated in time.

The treatment plan for patients with aggressive breast cancer is usually a combination of chemotherapy, radiation therapy, and surgery. However, despite the aggressive treatment, there is still a risk of relapse, which can be devastating for the patient and their families.

A new therapy has been developed that can help to reduce the risk of relapse in aggressive breast cancer patients. In this article, we will explore the new therapy and its benefits in reducing the risk of relapse in aggressive breast cancer patients.

Understanding Aggressive Breast Cancer

Aggressive breast cancer is a type of cancer that grows quickly and spreads rapidly to other parts of the body.

This type of breast cancer is also known as triple-negative breast cancer, which means it does not have the receptors for estrogen, progesterone, and HER2.

Aggressive breast cancer accounts for about 10-20% of all breast cancer cases and is more commonly found in younger women and African-American women. The symptoms of aggressive breast cancer include a lump in the breast, swelling, redness, and pain.

Current Treatment for Aggressive Breast Cancer

Aggressive breast cancer is usually treated with a combination of chemotherapy, radiation therapy, and surgery. The primary treatment is chemotherapy, which is used to shrink the tumor and prevent it from spreading to other parts of the body.

Radiation therapy is used to kill any remaining cancer cells in the breast tissue, and surgery is used to remove the tumor and surrounding tissue.

The treatment plan for aggressive breast cancer can be challenging and can take a toll on the patient’s physical and emotional well-being.

Despite the aggressive treatment, there is still a risk of relapse, which can occur within the first few years after treatment.

New Therapy for Reducing the Risk of Relapse

A new therapy has been developed that can help to reduce the risk of relapse in aggressive breast cancer patients. The therapy targets a particular protein called CDK4/6, which is essential for cell division.

The therapy works by inhibiting the CDK4/6 protein, which prevents cancer cells from dividing and spreading to other parts of the body.

The therapy has been approved by the FDA for the treatment of advanced breast cancer. However, recent studies have shown that the therapy can also be beneficial for reducing the risk of relapse in aggressive breast cancer patients.

Benefits of the New Therapy

The new therapy has several benefits for aggressive breast cancer patients. Firstly, it reduces the risk of relapse, which can be devastating for the patient and their families.

Studies have shown that the therapy can reduce the risk of relapse by up to 33% in patients with aggressive breast cancer.

Secondly, the therapy has fewer side effects compared to traditional chemotherapy. The therapy targets cancer cells specifically, which reduces the damage to healthy cells and tissues in the body.

This results in fewer side effects, such as hair loss, nausea, and fatigue.

Thirdly, the therapy is administered orally, which is more convenient for the patient compared to traditional chemotherapy, which requires frequent hospital visits for intravenous injections.

Conclusion

Aggressive breast cancer is a type of breast cancer that spreads quickly and can result in high mortality rate if not treated in time.

Despite the aggressive treatment, there is still a risk of relapse, which can be devastating for the patient and their families. However, a new therapy has been developed that can help to reduce the risk of relapse in aggressive breast cancer patients.

The therapy targets a particular protein called CDK4/6, which is essential for cell division. The therapy works by inhibiting the CDK4/6 protein, which prevents cancer cells from dividing and spreading to other parts of the body.

The therapy has been approved by the FDA for the treatment of advanced breast cancer and has shown promising results in reducing the risk of relapse in aggressive breast cancer patients.